The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win

Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint.

Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events

Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.

Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies

Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.

Lateral Flow Assay Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035

The global lateral flow assay market is projected to grow from USD 10.84 billion in 2025 to USD 17.66 billion by 2035, with a 5.0% CAGR. Growth is driven by increased adoption of point-of-care testing, technological innovations including CRISPR-based assays, and the shift toward decentralized diagnostic models. Major players include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific, with infectious disease testing accounting for 72.2% of market share.

Breast Cancer Therapeutics Market Size to Reach USD 95.14 Billion at a CAGR of 9.20% from 2035 – SNS Insider

The global breast cancer therapeutics market is projected to grow from USD 39.46 billion in 2025 to USD 95.14 billion by 2035, with a CAGR of 9.20%. Growth is driven by increased adoption of targeted therapies, CDK4/6 inhibitors, immunotherapy, and antibody-drug conjugates. North America leads with 38.61% market share, while Asia Pacific shows the fastest growth. Targeted therapy dominates with 64.85% share, while immunotherapy is the fastest-growing segment at 14.25% CAGR.